Kuros Biosciences (CSBTF) Price & Analysis

Compare

13 Followers

CSBTF Stock Chart & Stats

$35.00

$0.26(0.95%)

At close: Jan 08 4:00 PM EST

$35.00

$0.26(0.95%)

Day’s Range― - ―

52-Week Range$18.95 - $42.81

Previous CloseN/A

Volume4.47K

Average Volume (3M)469.00

Market Cap

$1.16B

Enterprise Value$905.07M

Total Cash (Recent Filing)$15.66M

Total Debt (Recent Filing)$3.94M

Price to Earnings (P/E)498.6

Beta0.39

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.12

Shares Outstanding39,179,276

10 Day Avg. Volume795

30 Day Avg. Volume469

Financial Highlights & Ratios

PEG Ratio-3.21

Price to Book (P/B)15.78

Price to Sales (P/S)8.71

P/FCF Ratio-439.50

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue6.99

Enterprise Value/Gross Profit8.03

Enterprise Value/Ebitda88.76

Forecast

1Y Price Target

$47.98

Price Target Upside37.08% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.5

Revenue Forecast (FY)$287.77M

Bulls Say, Bears Say

Bulls Say

Revenue ScalingSustained multi-year revenue growth from ~4.0m to ~121.3m indicates durable commercial traction for MagnetOs and related products. This expanding top line supports market-share gains, creates operating leverage, and funds ongoing commercialization and R&D investments over the medium term.

High Gross MarginsVery high gross margins (~86% in 2025) reflect strong product economics and likely pricing power for core bone-graft technologies. Durable margins provide a structural buffer to absorb SG&A and support reinvestment, improving the company’s path to sustainable operating profitability.

Conservative Balance SheetExtremely low leverage and a growing asset base mean the company has financial flexibility. A conservative capital structure reduces refinancing risk, supports capacity and commercialization investments, and gives management runway to address cash-conversion issues without immediate distress.

Bears Say

Negative Cash GenerationOperating cash flow and free cash flow swung from positive in 2024 to negative in 2025, increasing near-term funding sensitivity. Persistent negative cash generation can force external financing or slower investment, constraining the company’s ability to scale sales and manufacturing sustainably.

Thin Net ProfitabilityThe company only recently turned profitable and net margins remain very thin. Limited earnings cushion makes results highly sensitive to reimbursement shifts, pricing pressure, or adoption lags, increasing the risk of reverting to losses if growth or pricing weakens.

Cash-Earnings DisconnectA disconnect between positive accounting earnings and negative cash conversion suggests working-capital or investment-driven cash drag. This structural mismatch can cause cash-flow volatility, elevate financing needs, and impede capacity or commercial expansion without additional capital.

Kuros Biosciences News

Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion

Kuros Biosciences ( ($CH:KURN) ) just unveiled an update. Kuros Biosciences reported a 72% jump in 2025 medical...

14d ago

Kuros Biosciences’ MagnetOs Study: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Study Overview: Kuros Biosciences is conducting a...

5M ago

CSBTF

Kuros Biosciences’ Clinical Study on MagnetOs Flex Matrix: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Kuros Biosciences is conducting a phase IV...

5M ago

CSBTF

Kuros Biosciences Reports Strong Revenue Growth and Strategic Expansion

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences announced a 77% year-over-year increase...

5M ago

Kuros Biosciences Investigates Allegations Against Former Board Member

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences is addressing media inquiries regarding the resignation...

6M ago

Kuros Biosciences Announces Board of Directors Changes

Kuros Biosciences ( ($CH:KURN) ) has provided an announcement. Kuros Biosciences announced changes to its Board of Directors,...

7M ago

Kuros Biosciences Reports Strong Revenue Growth in 2025

Kuros Biosciences ( ($CSBTF) ) has released its Q2 earnings. Here is a breakdown of the information Kuros...

7M ago

Kuros Biosciences Achieves Record Growth and First Operating Profit in H1 2025

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences reported a 78% increase in total medical...

7M ago

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported an 82% year-over-year increase...

11M ago

Kuros Biosciences Reports Strong Revenue Growth in 2024

Kuros Biosciences ( ($CSBTF) ) has released its Q4 earnings. Here is a breakdown of the information Kuros...

1y ago

CSBTF FAQ

What was Kuros Biosciences Ltd.’s price range in the past 12 months?

Kuros Biosciences Ltd. lowest stock price was $18.95 and its highest was $42.81 in the past 12 months.

What is Kuros Biosciences Ltd.’s market cap?

Kuros Biosciences Ltd.’s market cap is $1.16B.

When is Kuros Biosciences Ltd.’s upcoming earnings report date?

Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 141 days.

How were Kuros Biosciences Ltd.’s earnings last quarter?

Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported $0.118 earnings per share for the quarter, beating the consensus estimate of $0 by $0.118.

Is Kuros Biosciences Ltd. overvalued?

According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kuros Biosciences Ltd. pay dividends?

Kuros Biosciences Ltd. does not currently pay dividends.

What is Kuros Biosciences Ltd.’s EPS estimate?

Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kuros Biosciences Ltd. have?

Kuros Biosciences Ltd. has 39,179,276 shares outstanding.

What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?

Kuros Biosciences Ltd. reported an EPS of $0.118 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 10.105%.

Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?

Currently, no hedge funds are holding shares in CSBTF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kuros Biosciences Ltd.

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Kuros Biosciences (CSBTF) Earnings & Revenues

Historic Earnings Reports

CSBTF Company Deck

CSBTF Earnings Call

Q4 2026

0:00 / 0:00

CSBTF Stock 12 Month Forecast

Average Price Target

$47.98

▲(37.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","27":"$27","34":"$34","41":"$41","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.97918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.97918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.97918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,27,34,41,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.015,35.08916769230769,36.16333538461539,37.237503076923076,38.31167076923077,39.38583846153846,40.46000615384615,41.53417384615385,42.60834153846154,43.68250923076923,44.756676923076924,45.83084461538461,46.9050123076923,{"y":47.97918,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.015,35.08916769230769,36.16333538461539,37.237503076923076,38.31167076923077,39.38583846153846,40.46000615384615,41.53417384615385,42.60834153846154,43.68250923076923,44.756676923076924,45.83084461538461,46.9050123076923,{"y":47.97918,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.015,35.08916769230769,36.16333538461539,37.237503076923076,38.31167076923077,39.38583846153846,40.46000615384615,41.53417384615385,42.60834153846154,43.68250923076923,44.756676923076924,45.83084461538461,46.9050123076923,{"y":47.97918,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.12,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.82,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.015,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >